Vedere Bio II, Inc.® is a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death.

Biotechnology

Vedere Bio

Vedere Bio's headquarters in Cambridge, MA, United States

Karen Guerin

Daniel Zimmer

Ellen Zyrkowski

Soraya Bekkali, MD

Xiaozhi Ren (任小峙) Ph.D.

John Flannery

Ehud Isacoff

The Research and Development team at Vedere Bio focuses on pioneering ocular gene therapies to restore and preserve vision in patients suffering from vision loss due to photoreceptor death. This team drives innovative discovery research, develops cell lines and processes, and leads critical programs to advance therapeutic solutions from concept to clinical application.

Research and Development

The Leadership Team at Vedere Bio is responsible for setting the strategic direction of the company and overseeing the development of innovative ocular gene therapies. This team, comprised of co-founders and experts in science, regulatory affairs, and operations, collaborates to drive research initiatives, regulatory compliance, and operational efficiency, ensuring the successful translation of cutting-edge treatments into clinical practice for patients with vision loss.

Vedere Bio

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Offices

Vedere Bio

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Offices

Related companies